EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses

Toshinari Takamura iD, Kohei Kaku iD, Akihiro Yoshida, Hiromi Kusakabe, Hiroyuki Nakamura, Hideki Suganami iD

Endocrinology, Diabetes & Metabolism · 2024

DOI: 10.1002/edm2.461 ↗

At a glance

Journal article in Endocrinology, Diabetes & Metabolism, 2024. Written by Toshinari Takamura and 5 co-authors. Institution: Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Hyperglycemia, Benzhydryl Compounds. Cited 1 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY 4.0).

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Aims

How the pathology of type 2 diabetes (T2D), including hyperglycaemia and obesity, affects liver enzymes has not been clinically demonstrated. Thus, we compared time courses of gamma‐glutamyltransferase (GGT) and alanine aminotransferase (ALT) with those of fasting plasma glucose (FPG) and body weight (BW) during treatment with the SGLT2 inhibitor tofogliflozin for T2D. Materials and Methods We post‐hoc analysed preexisting data on 1046 people with T2D administered tofogliflozin or placebo for 24 weeks in four tofogliflozin studies. First, time courses of percent changes in variables during the intervention were analysed using a mixed effect model to explore the similarity of the time courses and to evaluate time‐treatment interactions. Second, clinical factors related to the percent changes in GGT and ALT were clarified using multivariate analyses.

Results

GGT levels and FPG values rapidly and significantly decreased via tofogliflozin as early as week 4, with decreases maintained until week 24. Conversely, BW and ALT decreased progressively until week 24. Time courses of FPG ( p = .365, time‐treatment interaction) and GGT ( p = .510) reductions were parallel between tofogliflozin and placebo from weeks 4 to 24, while BW and ALT reductions ( p < .001, respectively) were not. Reductions in GGT at week 24 were associated with reductions in FPG and BW at week 24, whereas ALT reductions were only associated with reductions in BW.

Conclusions

Reductions in GGT and ALT were associated with the anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin, respectively, in people with T2D. Therefore, GGT and ALT may be surrogate markers for hyperglycaemia and obesity in T2D.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHyperglycemiaBenzhydryl CompoundsGlucosidesHumansObesityBody Weightgamma-GlutamyltransferaseLiver

Author keywords

alanine aminotransferasefatty livergamma-glutamyltransferasesodium/glucose cotransporter 2 inhibitortofogliflozin

Substances

6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-tri…Sodium-Glucose Transporter 2 Inhibitorsgamma-GlutamyltransferaseBenzhydryl CompoundsGlucosides

Authors and institutions

  • Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
  • Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.
  • Kowa Co., Ltd., Tokyo, Japan.
  • Department of Hygiene and Public Health, , Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
  • Clinical Data Science Department, Kowa Co., Ltd., Tokyo, Japan.

ORCID profiles: Toshinari Takamura, Kohei Kaku, Hideki Suganami

Cite

APA

Takamura, T., Kaku, K., Yoshida, A., Kusakabe, H., Nakamura, H., & Suganami, H. (2024). Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.461

Vancouver

Takamura T, Kaku K, Yoshida A, Kusakabe H, Nakamura H, Suganami H. Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses. Endocrinology, Diabetes & Metabolism. 2024. doi:10.1002/edm2.461

BibTeX
@article{Takamura2024,
  author = {Takamura, Toshinari and Kaku, Kohei and Yoshida, Akihiro and Kusakabe, Hiromi and Nakamura, Hiroyuki and Suganami, Hideki},
  title = {Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2024},
  doi = {10.1002/edm2.461}
}
Start for free →